Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer
Metrics: PDF 1995 views | HTML 3196 views | ?
Hee Jin Lee1,*, Young-Ae Kim1,2,*, Chan Kyu Sim3,*, Sun-Hee Heo1,2, In Hye Song1, Hye Seon Park1,2, Suk Young Park1,2, Won Seon Bang1,2, In Ah Park1, Miseon Lee1, Jung Hoon Lee3, Yeon Sook Cho3, Suhwan Chang4, Jaeyun Jung4, Jisun Kim5, Sae Byul Lee5, Sung Youl Kim6, Myeong Sup Lee3,# and Gyungyub Gong5,#
1Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
2Asan Center for Cancer Genome Discovery, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
3Lab of Molecular Immunology and Medicine, Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul, Korea
4Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul, Korea
5Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
6R&D Center, GNSBio Co. Ltd., Gyeonggi-do, Korea
*These authors contributed equally to this work
#Authors share co-corresponding authorship
Gyungyub Gong, email: email@example.com
Myeong Sup Lee, email: firstname.lastname@example.org
Keywords: breast cancer; tumor-infiltrating lymphocyte; adoptive cell transfer; memory T cell; function of TIL
Received: July 12, 2017 Accepted: November 13, 2017 Published: December 06, 2017
Adoptive cell transfer (ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs) has been successful in treating a considerable proportion of patients with metastatic melanoma. In addition, some patients with several other solid tumors were recently reported to have benefited clinically from such ACT. However, it remains unclear whether ACT using TILs is broadly applicable in breast cancer, the most common cancer in women. In this study, the utility of TILs as an ACT source in breast cancers was explored by deriving TILs from a large number of breast cancer samples and assessing their biological potentials. We successfully expanded TILs ex vivo under a standard TIL culture condition from over 100 breast cancer samples, including all breast cancer subtypes. We also found that the information about the percentage of TIL and presence of tertiary lymphoid structure in the tumor tissues could be useful for estimating the number of obtainable TILs after ex vivo culture. The ex vivo expanded TILs contained a considerable level of central memory phenotype T cells (about 20%), and a large proportion of TIL samples were reactive to autologous tumor cells in vitro. Furthermore, the in vitro tumor-reactive autologous TILs could also function in vivo in a xenograft mouse model implanted with the primary tumor tissue. Collectively, these results strongly indicate that ACT using ex vivo expanded autologous TILs is a feasible option in treating patients with breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.